Category: Press Releases

Genprex Expands Executive Management Team and Completes Funding

Genprex, Inc. announces the appointment of Julien Pham, MD, MPH, as Chief Operating Officer.

Read More

Genprex Signs Capital Markets Advisory Agreement with Network 1 Financial as Part of an Overall Financing Plan

Genprex, Inc. announced today that it has signed a capital markets advisory agreement with Network 1 Financial Securities, Inc. as a first step in the Company’s plan for funding its capital needs as it enters into advanced clinical trials for its lead drug candidate.

Read More

Genprex Begins Phase II Clinical Trial for Lung Cancer

Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients.

Read More

Clinical Trial Highlights Positive Oncoprex Results in Lung Cancer Patients

A clinical trial has demonstrated that Oncoprex® (TUSC2 nanoparticles) can be safely administered in advanced lung cancer patients to halt cancer or shrink primary and metastatic tumors in some patients.

Read More

Oncoprex Shows Synergistic Tumor Suppression in Combination with AKT Inhibitor MK2206

New data demonstrating the anti-cancer activities of Oncoprex® were presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago IL.

Read More

Genprex Announces New Patent Issuance in Japan

A new patent covering tumor suppression technologies, including the company’s lead product candidate Oncoprex™, was recently awarded to The University of Texas System by the Japan Patent Office.

Read More

Genprex announces new branding

Genprex, Inc., formerly known as Convergen LifeSciences, Inc., announced today that its first product candidate, the nanomolecular cancer therapy CNVN202, will be branded as Oncoprex™.

Read More

Genprex announces patent award

Composition of Matter Patent Covers Broad Therapeutic and Diagnostic Applications

Read More

Genprex Announces Patent Award for Cancer Suppressors

AUSTIN, TX, June 28, 2011 – Genprex, Inc. announced today that a United States Patent has been awarded by the U.S. Patent and Trademark Office jointly to The University of Texas System Board of Regents and The Secretary, U.S. Department of Health and Human Services. U.S. Patent No. 7,902,441 is one of 23 patents

Read More

Clinical Trial Data Presented at the 2011 AACR Meeting

Oncoprex™ Phase I clinical trial data presented at the 2011 Annual Meeting of the American Association for Cancer Research in Orlando, Florida. Dr Charles Lu of MD Anderson Cancer Center presented the award winning abstract and poster describing the phase I

Read More

 
STAY IN THE KNOW WITH
EMAIL NEWS ALERTS
 
Don't miss out. Get our news delivered to your inbox.
 

 
close-link
 
Get Email News Alerts
 
close-link